1ysn: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Proteins in the Bcl-2 family are central regulators of programmed cell, death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are, overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with, chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase, sensitivity to anticancer drugs and enhance in vivo survival. The, development of inhibitors of these proteins as potential anti-cancer, therapeutics has been previously explored, but obtaining potent, small-molecule inhibitors has proved difficult owing to the necessity of, targeting a protein-protein interaction. Here, using nuclear magnetic, resonance (NMR)-based screening, parallel synthesis and structure-based, design, we have discovered ABT-737, a small-molecule inhibitor of the, anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to, three orders of magnitude more potent than previously reported compounds., Mechanistic studies reveal that ABT-737 does not directly initiate the, apoptotic process, but enhances the effects of death signals, displaying, synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737, exhibits single-agent-mechanism-based killing of cells from lymphoma and, small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of, established tumours, and produces cures in a high percentage of the mice.
Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.


==About this Structure==
==About this Structure==
Line 13: Line 13:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Armstrong, R.C.]]
[[Category: Armstrong, R C.]]
[[Category: Augeri, D.J.]]
[[Category: Augeri, D J.]]
[[Category: Belli, B.A.]]
[[Category: Belli, B A.]]
[[Category: Bruncko, M.]]
[[Category: Bruncko, M.]]
[[Category: Connor, J.M.O.]]
[[Category: Connor, J M.O.]]
[[Category: Deckwerth, T.L.]]
[[Category: Deckwerth, T L.]]
[[Category: Dinges, J.]]
[[Category: Dinges, J.]]
[[Category: Elmore, S.W.]]
[[Category: Elmore, S W.]]
[[Category: Fesik, S.W.]]
[[Category: Fesik, S W.]]
[[Category: Hajduk, P.J.]]
[[Category: Hajduk, P J.]]
[[Category: Joseph, M.K.]]
[[Category: Joseph, M K.]]
[[Category: Kitada, S.]]
[[Category: Kitada, S.]]
[[Category: Korsmeyer, S.J.]]
[[Category: Korsmeyer, S J.]]
[[Category: Kunzer, A.R.]]
[[Category: Kunzer, A R.]]
[[Category: Letai, A.]]
[[Category: Letai, A.]]
[[Category: Li, C.]]
[[Category: Li, C.]]
[[Category: Mitten, M.J.]]
[[Category: Mitten, M J.]]
[[Category: Nettesheim, D.G.]]
[[Category: Nettesheim, D G.]]
[[Category: Ng, S.]]
[[Category: Ng, S.]]
[[Category: Nimmer, P.M.]]
[[Category: Nimmer, P M.]]
[[Category: Oleksijew, A.]]
[[Category: Oleksijew, A.]]
[[Category: Oltersdorf, T.]]
[[Category: Oltersdorf, T.]]
[[Category: Petros, A.M.]]
[[Category: Petros, A M.]]
[[Category: Reed, J.C.]]
[[Category: Reed, J C.]]
[[Category: Rosenberg, S.H.]]
[[Category: Rosenberg, S H.]]
[[Category: Shen, W.]]
[[Category: Shen, W.]]
[[Category: Shoemaker, A.R.]]
[[Category: Shoemaker, A R.]]
[[Category: Tahir, S.K.]]
[[Category: Tahir, S K.]]
[[Category: Thompson, C.B.]]
[[Category: Thompson, C B.]]
[[Category: Tomaselli, K.J.]]
[[Category: Tomaselli, K J.]]
[[Category: Wang, B.]]
[[Category: Wang, B.]]
[[Category: Wendt, M.D.]]
[[Category: Wendt, M D.]]
[[Category: Zhang, H.]]
[[Category: Zhang, H.]]
[[Category: 43B]]
[[Category: 43B]]
Line 50: Line 50:
[[Category: complex]]
[[Category: complex]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 11:30:41 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:08:38 2008''